Imugene Limited (ASX:IMU) Doses First Australian Patient in Phase 1b Trial
First Patient Dosed
Imugene Limited (ASX:IMU) has successfully dosed its first Australian patient in the Phase 1b clinical trial of azer-cel (azercabtagene zapreleucel) at Royal Prince Alfred Hospital in Sydney. The trial targets relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a challenging form of non-Hodgkin’s lymphoma.
Clinical Insights
The trial follows promising results from Imugene’s US cohorts, where three patients achieved complete responses despite prior treatment failures. Patients in the trial are expected to benefit from azer-cel’s off-the-shelf approach, which differs from traditional therapies that require lengthy manufacturing processes using a patient’s own cells. This methodology aims to shorten treatment timelines and enhance accessibility for patients.
Executive Comment
Leslie Chong, Managing Director and CEO of Imugene, emphasised the significance of this milestone: “Achieving first patient dosed for azer-cel in Australia represents a significant milestone for Imugene and for Australian patients battling this devastating disease.” She further noted the trial’s potential to improve outcomes for patients with limited options.
About the Trial
The Phase 1b trial is an open-label, multi-centre study examining the safety and efficacy of azer-cel in patients who have already received autologous CAR T-cell therapies. The study incorporates a combination of lymphodepletion chemotherapy and interleukin-2 (IL-2) to potentially enhance the therapeutic effects of azer-cel.
Motley Fool contributor Aaron Shaw has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.